Acute Intermittent Porphyria Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

Acute intermittent porphyria is a condition wherein the patient suffers from acute attacks of porphyria. The acute intermittent porphyria market is expected to grow at a CAGR of 7% from 2024 to 2032. This will be a result of the following factors: AIP cases are increasing, which is leading to an increase in awareness and better diagnostics, which in turn is resulting in an increase in demand for effective treatment options. Advancements in genetic research and development of targeted therapies will improve the patient outcome, which in turn will drive the market growth. The major players in the AIP market, such as Alnylam and Recordati, are engaged in the development of novel drugs. Alnylam’s launch of a therapy for the underlying cause of AIP has attracted significant interest and investment. Strategic collaborations and strategic alliances in the pharmaceutical industry will further promote the development of new drugs. The integration of technology in drug development and patient care is expected to play a significant role in the future of the AIP market.

Regional Market Size

Regional Deep Dive

Acute intermittent porphyria (AIP) market is characterized by a rising awareness of the disease and the technological advancements in the treatment of the disease across various regions. In North America, the market is driven by a strong health care system and an increasing research budget, whereas in Europe, the market is driven by strong regulatory framework and patient support groups. In the Asia-Pacific region, the diagnosis rate is increasing due to the increasing health care system, whereas in the Middle East and Africa, the awareness and the lack of resources are the major restraints to the growth of the market. Latin America is developing its market slowly with the emergence of health care policies related to rare diseases, such as AIP. In the end, the market dynamics are mainly influenced by regional health care policies, cultural perceptions of rare diseases, and the availability of new therapies.

Europe

• The European Medicines Agency (EMA) has implemented streamlined approval processes for orphan drugs, facilitating quicker access to innovative treatments for AIP patients.
• Several European countries are investing in genetic research and patient registries to better understand AIP, which is expected to lead to improved diagnostic and therapeutic strategies.

Asia Pacific

• Countries like Japan and Australia are increasing their focus on rare diseases, with government initiatives aimed at enhancing research funding and patient support for conditions like AIP.
• The rise of telemedicine in the region is improving access to specialists for AIP patients, particularly in rural areas where healthcare resources are limited.

Latin America

• Emerging healthcare policies in countries like Brazil and Mexico are starting to recognize the importance of rare diseases, leading to increased funding for research and treatment options for AIP.
• Patient advocacy groups are gaining momentum in Latin America, pushing for better healthcare access and awareness of AIP, which is expected to drive market growth.

North America

• The U.S. Food and Drug Administration (FDA) has recently approved new therapies specifically targeting AIP, which is expected to enhance treatment options and improve patient outcomes.
• Organizations like the American Porphyria Foundation are actively working to raise awareness and provide resources for patients, which is crucial for early diagnosis and management of AIP.

Middle East And Africa

• Awareness campaigns led by local health ministries and NGOs are beginning to address the stigma associated with rare diseases, including AIP, which is crucial for improving diagnosis rates.
• Collaborations between international pharmaceutical companies and local healthcare providers are emerging to enhance treatment access and education about AIP in underserved regions.

Did You Know?

“Acute Intermittent Porphyria is one of the most common types of porphyria, yet it is often misdiagnosed due to its diverse symptoms, which can mimic other conditions.” — American Porphyria Foundation

Segmental Market Size

Acute Intermittent Porphyria is a segment of the porphyria market that is currently experiencing stable growth, resulting from a greater awareness and diagnosis of the disease. The development of genetic testing and the emergence of a patient-tailored approach to treatment are the main factors driving the market. In addition, regulatory support, such as the recent approval of new therapies by the FDA, is further increasing the market’s momentum. The AIP treatment market is currently in the transition from pilot to implementation, with the introduction of a new treatment, such as givosiran, by Alnylam. Managing acute attacks and symptom control are the main uses of these treatments, particularly in specialized clinics and hospitals. This is a growing market, which is gaining momentum from the increasing number of rare diseases and from an increase in research into rare diseases. CRISPR and NGS are also influencing the development of the market, with more precise interventions and better patient outcomes.

Future Outlook

Acute Intermittent Porphyria (AIP) is forecast to see substantial growth from 2024 to 2032, with a projected rise from $ 4.61 billion to $ 7.34 billion, a CAGR of 6.9 percent. The soaring numbers are attributed to the growing prevalence of the disease, the rise in awareness amongst the medical fraternity, and the development of diagnostic tools. In the coming years, the understanding of porphyria is expected to increase. This, in turn, is likely to lead to a rise in the number of patients diagnosed and treated. The number of patients who are treated is expected to rise to approximately 25 percent of the total number of patients by 2032, up from 15 percent in 2024. The market is also slated to be bolstered by the development of novel therapies, including gene therapies and small molecule drugs that target the underlying metabolic pathways of AIP. Also, supportive government policies and initiatives aimed at improving access to specialized care are expected to help in the adherence and outcomes of treatment. Meanwhile, emerging trends such as the integration of digital health and precision medicine are expected to further shape the market, with more tailored treatment regimens and improved patient management. These changes will bring new opportunities for players in the market.